SARS-CoV-2 variant of concern

SARS-CoV-2 variant of concern
The term variant of concern (VOC) for SARS-CoV-2, which causes COVID-19, is a category used for variants of the virus where mutations in their spike protein receptor binding domain (RBD) substantially increase binding affinity (e.g., N501Y) in RBD-hACE2 complex (genetic data), while also being linked to rapid spread in human populations (epidemiological data).
Before being allocated to this category, an emerging variant may have been labeled a variant of interest (VOI), or in some countries a variant under investigation (VUI). During or after fuller assessment as a variant of concern the variant is typically assigned to a lineage in the Pango nomenclature system and to clades in the Nextstrain and GISAID systems.
During the COVID-19 pandemic, the SARS-CoV-2 virus has been observed to mutate, with certain combinations of specific point mutations proving to be more concerning than others. This was principally for reasons of transmissibility and virulence, and also with regard to the possible emergence of escape mutations.
Criteria
Several national and international health organisations (e.g. Centers for Disease Control and Prevention (CDC) (US), Public Health England (PHE) and the COVID-19 Genomics UK Consortium for the UK, and the Canadian COVID Genomics Network (CanCOGeN)) use some or all of the following criteria to assess variants:
Increased transmissibility
Increased morbidity
Increased mortality
Increased risk of "long COVID"
Ability to evade detection by diagnostic tests
Decreased susceptibility to antiviral drugs (if and when such drugs are available)
Decreased susceptibility to neutralizing antibodies, either therapeutic (e.g., convalescent plasma or monoclonal antibodies) or in laboratory experiments
Ability to evade natural immunity (e.g., causing reinfections)
Ability to infect vaccinated individuals
Increased risk of particular conditions such as multisystem inflammatory syndrome or long-haul COVID.
Increased affinity for particular demographic or clinical groups, such as children or immunocompromised individuals.
Variants that appear to meet one or more of these criteria may be labeled "variants of interest" or "variants under investigation" ('VUI') pending verification and validation of these properties. Once validated, variants of interest /VUI may be renamed "variants of concern" by monitoring organizations, such as the CDC. A related category is "variant of high consequence", used by the CDC if there is clear evidence that the effectiveness of prevention or intervention measures for a particular variant is substantially reduced.
Classifications by country
World Health Organization
The WHO maintains a list of variants of global concern. On 26 November 2021, the WHO added a fifth variant of concern, the Omicron variant, previously known as B.1.1.529. Omicron joins the Alpha, Beta, Gamma, and Delta variants.
Africa
The NICD in South Africa maintains a list of variants and testing facilities locally in collaboration with KRISP.
Europe
As of November 2021, the European Centre for Disease Prevention and Control declared four variants to be 'variants of concern': Beta, Gamma, Delta, and B.1.1.529 (named 'Omicron' after the reference was updated); Mu, Lambda and AY.4.2 were named as Variants of Interest (VOI), while there were 9 'Variants under monitoring'. 25 variants were described as 'de-escalated'.
United Kingdom
As of November 2021, the United Kingdom has fifteen variants on its 'watch list', 4 with 'VOC' status and 11 rated as 'VUI'. Those designated 'VOC' were Alpha, Beta, Gamma, and Delta. In early December 2021, Omicron was added to the VOCs. Among the Variants under investigation is 'VUI-21OCT-01/ A.Y 4.2'.
North America
Canada (via health-infobase.canada.ca) and the United States (via the CDC) also maintain lists of variants of concern. As of early December, Canada was monitoring five variants of concern: Alpha, Beta, Gamma, Delta, and Omicron, while the US was monitoring two: Delta and Omicron.
References